"Quinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011804
|
| MeSH Number(s) |
D03.633.100.810
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinolines".
Below are MeSH descriptors whose meaning is more specific than "Quinolines".
This graph shows the total number of publications written about "Quinolines" by people in this website by year, and whether "Quinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 3 | 2 | 5 |
| 2006 | 4 | 1 | 5 |
| 2007 | 3 | 3 | 6 |
| 2008 | 0 | 4 | 4 |
| 2009 | 8 | 1 | 9 |
| 2010 | 4 | 2 | 6 |
| 2011 | 3 | 8 | 11 |
| 2012 | 8 | 7 | 15 |
| 2013 | 2 | 6 | 8 |
| 2014 | 5 | 6 | 11 |
| 2015 | 12 | 4 | 16 |
| 2016 | 8 | 4 | 12 |
| 2017 | 15 | 4 | 19 |
| 2018 | 9 | 3 | 12 |
| 2019 | 6 | 5 | 11 |
| 2020 | 5 | 4 | 9 |
| 2021 | 11 | 13 | 24 |
| 2022 | 3 | 3 | 6 |
| 2023 | 4 | 0 | 4 |
| 2024 | 9 | 4 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolines" by people in Profiles.
-
Dual optical elastography detects TGF-? -induced alterations in the biomechanical properties of skin scaffolds. J Biomed Opt. 2024 Sep; 29(9):095002.
-
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Sep 03; 30(17):3757-3767.
-
Symmetry breaking of fluorophore binding to a G-quadruplex generates an RNA aptamer with picomolar KD. Nucleic Acids Res. 2024 Aug 12; 52(14):8039-8051.
-
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia. Ann Hematol. 2024 Sep; 103(9):3429-3442.
-
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann Oncol. 2024 Nov; 35(11):993-1002.
-
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist. 2024 Jul 05; 29(7):589-595.
-
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Oct 24; 391(16):1486-1498.
-
Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data. Mult Scler. 2024 May; 30(6):696-706.
-
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. Eur Urol. 2024 Jul; 86(1):4-9.
-
Thyroid Cancer: A Review. JAMA. 2024 02 06; 331(5):425-435.